A Study of CA201A Eye Drops to Prevent Corneal Endothelial Cell Loss in Patients Undergoing Cataract Surgery

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Corneal Endothelial Cell Loss, Corneal Endothelial Damage Following the Hard Nuclear Cataract Surgery

In brief

This study is designed to assess whether an investigational eye drop called CA201A can help protect the cornea (the outer covering of the eye) and reduce damage to corneal endothelial cells following cataract surgery, without causing significant side effects. Cataract surgery is one of the common surgical procedures, however, it can sometimes lead to a loss of corneal endothelial cells, which are essential for maintaining the corneal clarity and long-term eye health. About 200 adults in Australia who are scheduled to have cataract surgery will be enrolled in this study following eligibility check. All eligible participants will be randomly assigned (by chance) to receive either the CA201A eye drops or a similar eye drop without the active ingredient. Neither the participant nor the study doctor will know the treatment each participant is receiving until the study is completed. All enrolled participants will place 1 drop of CA201A four times daily, starting 7 days prior to the surgery, continue on the day of surgery, and then keep using them for 4 weeks following surgery. After treatment, participants will be followed for up to 12 weeks after surgery in order to monitor safety and assess how well the treatment works. All participants will undergo standard cataract surgery and receive usual care; the study eye drops will be given in addition to this routine treatment. Throughout the study, doctors will measure changes in corneal endothelial cell density and perform other eye examinations to evaluate the treatment effect.

Key facts

Study ID

NCT07694375

Run by

Caravel Oculus Pty Ltd

People needed

200

Starts

2026-07-28

Expected to finish

2027-02-01

Last updated by the study team

2026-08-06

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• The subject must voluntarily sign and date a Human Research Ethics Committee (HREC) approved informed consent form (ICF) prior to the initiation of any screening or study-specific procedures.
• In the Investigator's opinion, the subject is willing and able to comply with study instructions and complete all scheduled study visits.
• Male or female aged ≥18 and ≤85 years.
• Scheduled to undergo cataract extraction by phacoemulsification with implantation of a posterior chamber intraocular lens.
• Has the potential to improve best-corrected visual acuity (BCVA) in the study eye following surgery, as judged by the Investigator.
• Has a nuclear cataract exhibiting a nuclear opalescence of Grade 3, 4, or 5 in the study eye according to the Lens Opacities Classification System III (LOCS III) classification. This includes pure nuclear cataracts as well as mixed-type cataracts (ie, nuclear opalescence grade 3 to 5 with or without co-existing cortical and/or posterior subcapsular opacities).
• Has corneal endothelium in the study eye that can be adequately assessed using specular microscopy, with sufficient image quality for endothelial cell density analysis.
• Has a central corneal ECD ≥1000 cells/mm² in the study eye at the Screening visit, as measured by specular microscopy.
• Has a pinhole visual acuity of ≥35 Early Treatment Diabetic Retinopathy Study (ETDRS) letters (approximately equivalent to 6/60 Snellen) in the study eye at the Screening visit, measured using an ETDRS chart at 4 meters. The fellow eye must have visual acuity sufficient, in the opinion of the Investigator, to allow safe postoperative function.
• Female subjects must be of nonchildbearing potential or have a negative pregnancy test at Screening and agree to use appropriate contraception throughout the study.
• Male subjects with female partners of childbearing potential must agree to use appropriate contraception and refrain from sperm donation during the study.

You may not qualify if…

• Ocular Exclusions (Study Eye):
• Active immunosuppressive or autoimmune disease that, in the opinion of the Investigator, could affect ocular surface integrity.
• Active or chronic/recurrent ocular or systemic disease that is uncontrolled and likely to impair wound healing.
• Intraocular pressure (IOP) ≤6 mmHg in either eye at screening.
• Clinically significant Fuchs' endothelial corneal dystrophy (Grade 4 or higher on clinical examination).
• History of corneal transplantation or other corneal surgery.
• History of intraocular surgery in the study eye within 6 months of screening (except YAG laser capsulotomy >3 months prior to screening).
• Planned combined cataract surgery with other intraocular procedures (eg, glaucoma surgery, vitrectomy).
• Active ocular infection or inflammation in either eye.
• Uncontrolled glaucoma (intraocular pressure >25 mmHg on maximum tolerated medical therapy) in the study eye.
• Significant corneal opacity, scarring, or irregularity that would interfere with accurate specular microscopy assessment (including cases where image acquisition or analysis is not feasible).
• History of uveitis or other chronic inflammatory eye disease in the study eye.
• Proliferative diabetic retinopathy or active retinal disease in the study eye, that in the Investigator's opinion, may increase surgical risk or confound postoperative assessments.
• Any other ocular condition that, in the opinion of the Investigator, may interfere with study assessments or subject safety.
• History of corneal or retinal surgery (laser or incisional) in the study eye within 6 months, or planned ocular surgery during the study period.
• Presence of severe corneal guttae or other abnormalities in the study eye that, in the opinion of the Investigator, preclude reliable endothelial cell assessment by specular microscopy.
• Anticipated complex cataract surgery in the study eye that, in the opinion of the Investigator, is likely to substantially increase endothelial injury risk or require nonstandard surgical techniques (eg, brunescent or hypermature cataract, significant zonular instability requiring planned capsular support devices, or other features expected to materially prolong phacoemulsification).
• Specular microscopy images that are not gradable at Screening despite repeat acquisition attempts.
• Systemic Exclusions:
• Known hypersensitivity to ascorbic acid or any component of the study drug or vehicle.
• Current use of systemic ascorbic acid supplementation (oral or intravenous) >500 mg/day (Subjects taking ≤500 mg/day may continue their current regimen).
• History of calcium oxalate nephrolithiasis (kidney stones) within the past 5 years.
• Severe renal impairment (estimated glomerular filtration rate <30mL/min/1.73 m²).
• Known glucose-6-phosphate dehydrogenase (G6PD) deficiency associated with clinically significant hemolytic risk.
• Pregnant or breastfeeding women.

Where it is running

• Sydney Retina Clinic & Day Surgery — Sydney, New South Wales, Australia (enrolling)
• Eastwood Eye Specialists — Eastwood, New South Wales, Australia (enrolling)
• Nexus Eye Care Blacktown — Blacktown, New South Wales, Australia
• Adelaide Eye and Retina Centre — Adelaide, South Australia, Australia
• Hobart Eye Surgeons — Hobart, Tasmania, Australia
• Canberra Eye Surgeons — Deakin, Australian Capital Territory, Australia
• Launceston Eye Doctors — Launceston, Tasmania, Australia
• Nexus Eye Care Norwest — Baulkham Hills, New South Wales, Australia

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.